chlormadinone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
600 302-22-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • chlormadinone
  • chlormadinone acetate
  • chlormadinon
  • chlormadinon acetate
  • menstridyl
An orally active synthetic progestational hormone used often in combinations as an oral contraceptive (CONTRACEPTIVES, ORAL).
  • Molecular weight: 404.93
  • Formula: C23H29ClO4
  • CLOGP: 3.98
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 60.44
  • ALOGS: -5.41
  • ROTB: 3

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 24 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MET,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIM2,PRKDC,STK33,SYK,TEK,TTK,ZAP70 37
kinase-selectivity-class EIF2AK3,GRK2 2
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.66

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Meningioma 215.96 38.18 42 1597 5029 90621779
Ulnar tunnel syndrome 83.07 38.18 9 1630 9 90626799
Diabetic metabolic decompensation 52.20 38.18 11 1628 1946 90624862
Menometrorrhagia 44.89 38.18 9 1630 1246 90625562
Intermenstrual bleeding 43.84 38.18 13 1626 9210 90617598
Scar 41.18 38.18 14 1625 15381 90611427
Attention deficit hyperactivity disorder 38.95 38.18 10 1629 4174 90622634

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Meningioma 190.58 33.13 36 1283 5629 110582351
Ulnar tunnel syndrome 86.34 33.13 9 1310 10 110587970
Menometrorrhagia 51.57 33.13 9 1310 897 110587083
Diabetic metabolic decompensation 49.25 33.13 11 1308 3878 110584102
Intermenstrual bleeding 38.07 33.13 10 1309 6924 110581056
Avoidant personality disorder 36.57 33.13 5 1314 98 110587882
Claustrophobia 34.46 33.13 7 1312 1572 110586408

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G03AA15 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AB07 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, sequential preparations
ATC G03DB06 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
PROGESTOGENS
Pregnadien derivatives
ATC G03FB03 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
PROGESTOGENS AND ESTROGENS IN COMBINATION
Progestogens and estrogens, sequential preparations
MeSH PA D000080066 Contraceptive Agents, Hormonal
MeSH PA D000726 Androgen Antagonists
MeSH PA D003271 Contraceptive Agents, Female
MeSH PA D003278 Contraceptives, Oral, Hormonal
MeSH PA D003280 Contraceptives, Oral, Synthetic
MeSH PA D006727 Hormone Antagonists
MeSH PA D012102 Reproductive Control Agents

Related Drugs by ATC class:

G03AA Progestogens and estrogens, fixed combinations 17 drugs
desogestreldienogestdrospirenoneestetrolestradiolethinylestradioletynodiolgestodenelevonorgestrellynestrenolmedroxyprogesteronemegestrol acetate show all 17 →
G03AB Progestogens and estrogens, sequential preparations 10 drugs
desogestreldienogestestradiolethinylestradiolgestodenelevonorgestrellynestrenolmegestrol acetatenorethisteronenorgestimate
G03DB Pregnadien derivatives 7 drugs
demegestonedienogestdydrogesteronemedrogestonemegestrol acetatenomegestrolpromegestone
G03FB Progestogens and estrogens, sequential preparations 10 drugs
desogestreldydrogesteronelevonorgestrellynestrenolmedrogestonemedroxyprogesteronemegestrol acetatenomegestrolnorethisteronetrimegestone

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Endometriosis indication 129103003
Menorrhagia indication 386692008




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor Ki 7.76 DRUG MATRIX
Cytochrome P450 2C19 Enzyme IC50 5.52 DRUG MATRIX
Sodium/potassium-transporting ATPase subunit alpha-2 Ion channel IC50 5.34 DRUG MATRIX
Androgen receptor Transcription factor Ki 7.68 DRUG MATRIX
Progesterone receptor Transcription factor Ki 9.16 DRUG MATRIX

External reference:

IDSource
D01299 KEGG_DRUG
1961-77-9 SECONDARY_CAS_RN
2369 RXNORM
C0008214 UMLSCUI
CHEBI:31394 CHEBI
CHEMBL110691 ChEMBL_ID
CHEMBL1697830 ChEMBL_ID
DB13528 DRUGBANK_ID
D002715 MESH_DESCRIPTOR_UI
5284533 PUBCHEM_CID
1210 INN_ID
SDS4N642GG UNII
DB15903 DRUGBANK_ID
001294 NDDF
004937 NDDF
734645001 SNOMEDCT_US
734647009 SNOMEDCT_US
SDS4N642GG INXIGHT DRUGS

Pharmaceutical products:

None